ES2548766T3 - Efectos terapéuticos de las briostatinas, briólogos y otras sustancias relacionadas en alteraciones de la memoria inducidas por trauma craneal y por lesiones cerebrales - Google Patents

Efectos terapéuticos de las briostatinas, briólogos y otras sustancias relacionadas en alteraciones de la memoria inducidas por trauma craneal y por lesiones cerebrales Download PDF

Info

Publication number
ES2548766T3
ES2548766T3 ES08725395.1T ES08725395T ES2548766T3 ES 2548766 T3 ES2548766 T3 ES 2548766T3 ES 08725395 T ES08725395 T ES 08725395T ES 2548766 T3 ES2548766 T3 ES 2548766T3
Authority
ES
Spain
Prior art keywords
pkc
days
pharmaceutical composition
trauma
briostatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08725395.1T
Other languages
English (en)
Spanish (es)
Inventor
Ofer Zohar
Daniel L. Alkon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blanchette Rockefeller Neuroscience Institute
Original Assignee
Blanchette Rockefeller Neuroscience Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blanchette Rockefeller Neuroscience Institute filed Critical Blanchette Rockefeller Neuroscience Institute
Application granted granted Critical
Publication of ES2548766T3 publication Critical patent/ES2548766T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES08725395.1T 2007-02-09 2008-02-11 Efectos terapéuticos de las briostatinas, briólogos y otras sustancias relacionadas en alteraciones de la memoria inducidas por trauma craneal y por lesiones cerebrales Active ES2548766T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90033807P 2007-02-09 2007-02-09
US900338P 2007-02-09
US92466307P 2007-05-24 2007-05-24
US924663P 2007-05-24
PCT/US2008/001755 WO2008100449A2 (en) 2007-02-09 2008-02-11 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury

Publications (1)

Publication Number Publication Date
ES2548766T3 true ES2548766T3 (es) 2015-10-20

Family

ID=39690678

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08725395.1T Active ES2548766T3 (es) 2007-02-09 2008-02-11 Efectos terapéuticos de las briostatinas, briólogos y otras sustancias relacionadas en alteraciones de la memoria inducidas por trauma craneal y por lesiones cerebrales

Country Status (8)

Country Link
US (2) US9974832B2 (cg-RX-API-DMAC7.html)
EP (4) EP2121000B1 (cg-RX-API-DMAC7.html)
JP (3) JP5518489B2 (cg-RX-API-DMAC7.html)
KR (2) KR20090119894A (cg-RX-API-DMAC7.html)
CN (1) CN101848726A (cg-RX-API-DMAC7.html)
CA (2) CA2873179A1 (cg-RX-API-DMAC7.html)
ES (1) ES2548766T3 (cg-RX-API-DMAC7.html)
WO (1) WO2008100449A2 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1549721B (zh) 2001-02-27 2012-03-07 布朗歇特洛克菲勒神经科学研究所 基于促分裂原活化的蛋白激酶的磷酸化诊断阿尔茨海默氏病
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
CA2617003A1 (en) 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
US9974832B2 (en) 2007-02-09 2018-05-22 Cognitive Research Enterprises, Inc. Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
CN101678080A (zh) * 2007-02-09 2010-03-24 布朗歇特洛克菲勒神经科学研究所 苔藓抑素、苔藓抑素类似物和其它相关物质对缺血/中风引起的记忆缺陷和脑损伤的疗效
WO2008143880A2 (en) * 2007-05-24 2008-11-27 Blanchette Rockefeller Neurosciences Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and traumatic brain injury
US20100168219A1 (en) * 2008-12-31 2010-07-01 Jonathan Steven Alexander Chronic inflammation and transplantation
US9994585B2 (en) 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
US8822166B2 (en) 2008-07-28 2014-09-02 Blanchette Rockefeller Neurosciences Institute Stimulus-elicited genomic profile markers of alzheimer's disease
US8163800B2 (en) 2008-07-28 2012-04-24 Blanchette Rockefeller Neurosciences Institute PKC-activating compounds for the treatment of neurodegenerative diseases
US20110054040A1 (en) * 2008-12-22 2011-03-03 Department Of Biotechnology Bicyclic Triterpenoid Iripallidal as a Novel Anti-Glioma and Anti-Neoplastic Therapy
CN102741696A (zh) 2009-10-02 2012-10-17 布朗歇特洛克菲勒神经科学研究所 阿尔茨海默病外周细胞中pkc同工酶加工的异常改变
US8658134B2 (en) 2009-10-02 2014-02-25 Blanchette Rockefeller Neurosciences Institute Fibroblast growth patterns for diagnosis of Alzheimer's disease
JP6446624B2 (ja) 2010-07-08 2019-01-09 アルコン、ダニエル・エル． 脳卒中の治療法におけるｐｋｃ活性化因子および抗凝血剤
KR101467605B1 (ko) * 2010-11-29 2014-12-04 충북대학교 산학협력단 신규의 다프난 디테르펜계 화합물 및 이를 유효성분으로 포함하는 피부 미백용 조성물
JP6563193B2 (ja) 2011-11-13 2019-08-21 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Ｄｃｐｌａのエステル、およびそれを用いた処置の方法
US9034347B2 (en) 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
JP6579956B2 (ja) 2012-11-28 2019-09-25 アフィオス コーポレーション 神経変性疾患および他の疾患の治療のための併用治療薬および方法
CA2906164A1 (en) 2013-03-15 2014-09-18 Daniel L. Alkon Methods for identifying neuroprotective pkc activators
EP3501519B1 (en) 2016-08-18 2024-11-20 National University Corporation Nara Institute of Science and Technology Bryostatin 1 for use in treating ige mediated allergic diseases
EP3964210A1 (en) * 2018-05-18 2022-03-09 Neurotrope Bioscience, Inc. Methods and compositions for treatment of alzheimer's disease

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560774A (en) * 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
EP0115472A3 (de) 1983-01-27 1985-10-02 Ciba-Geigy Ag Pyrrolidinonderivate und Verfahren zu ihrer Herstellung
US4611066A (en) * 1984-08-10 1986-09-09 Arizona State University Bryostatins 4 to 8
US5962498A (en) 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US6043270A (en) 1986-06-11 2000-03-28 Procyon Pharmaceuticals, Inc. Protein kinase C modulators V
US5891906A (en) * 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Polyacetate-derived phorboids having anti-inflammatory and other uses
US6080784A (en) 1986-06-11 2000-06-27 Procyon Pharmaceuticals, Inc. Protein kinase C modulators N
US5955501A (en) 1986-06-11 1999-09-21 Procyon Pharmaceuticals, Inc. Protein kinase C modulators O
US5891870A (en) 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Protein kinase C modulators Q
US4833257A (en) 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
ES2061963T3 (es) 1988-01-13 1994-12-16 Univ Arizona State Briostatinas inmunomoduladoras.
US4833139A (en) * 1988-01-25 1989-05-23 Hoechst-Roussel Pharmaceuticals, Inc. Enhancing cholinergic activity with 5-substituted 1-[4-(1-pyrrolidinyl)-2-butynyl]-2-pyrrolidinones and related compounds
DE3827974A1 (de) 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US4994472A (en) 1989-08-02 1991-02-19 Hoechst-Roussel Pharmaceuticals Incorporated 1-(pyridinylamino)-2-pyrrolidinones as pain relievers
AU6886791A (en) 1989-11-13 1991-06-13 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
JP2578001B2 (ja) 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬
EP1046421B8 (en) 1990-12-06 2006-01-11 Affymetrix, Inc. (a Delaware Corporation) Methods and reagents for very large scale immobilized polymer synthesis
US5072004A (en) 1990-12-31 1991-12-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthetic conversion of bryostatin 2 into bryostatin 1
US5981165A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
US5196447A (en) 1991-08-08 1993-03-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting On Behalf Of Arizona State University Neristatin 1
ATE262374T1 (de) 1991-11-22 2004-04-15 Affymetrix Inc Kombinatorische strategien für polymersynthese
US5359115A (en) 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
HUT72495A (en) 1992-10-01 1996-05-28 Cold Spring Harbor Lab Complex combinatorial chemical libraries encoded with tags
JPH06279311A (ja) 1993-03-26 1994-10-04 Sagami Chem Res Center プロテインキナーゼｃアイソザイムの活性化剤
US5580748A (en) * 1993-05-03 1996-12-03 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic tests for alzheimers disease
US5976816A (en) * 1993-05-03 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Cell tests for alzheimer's disease
US5393897A (en) 1993-07-02 1995-02-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of spongistatins 5,7,8 and 9
US5362899A (en) 1993-09-09 1994-11-08 Affymax Technologies, N.V. Chiral synthesis of alpha-aminophosponic acids
EP0721945B1 (en) 1993-09-30 1999-02-24 Shionogi & Co., Ltd. Benzolactam derivative
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5430053A (en) * 1994-04-19 1995-07-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of dictyostatin 1
US5625232A (en) * 1994-07-15 1997-04-29 Texas Instruments Incorporated Reliability of metal leads in high speed LSI semiconductors using dummy vias
ES2194054T3 (es) 1994-11-10 2003-11-16 Pfizer Compuestos de lactona macrociclica y su procedimiento de produccion.
GB9509572D0 (en) 1995-05-11 1995-07-05 Cancer Res Campaign Tech Cancer therapy
EP0918757A1 (en) 1996-05-10 1999-06-02 Georgetown University 8-hydrocarbyl substituted benzodizocine derivatives, their preparation and their use as protein kinase c (=pkc) modulators
GB9620390D0 (en) * 1996-09-30 1996-11-13 Eisai London Res Lab Ltd Substances and their uses
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9701675D0 (en) 1997-01-28 1997-03-19 Bridgeman Keith Composition for the treatment of parkinson's disease
KR20010023741A (ko) 1997-09-08 2001-03-26 윌리암 제이.하트만 치환된 2-피롤리디논 ｐｋｃ 활성제
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
DE19943198A1 (de) 1999-09-09 2001-03-15 Meyer Lucas Gmbh & Co Therapeutikum zur Behebung zentralnervöser Funktionsstörungen
JP2003515601A (ja) * 1999-11-30 2003-05-07 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ ブリオスタチンアナログ、合成方法および使用
JP2001240581A (ja) 2000-02-29 2001-09-04 Senju Pharmaceut Co Ltd アミノベンズアミド誘導体およびその用途
AU2001243635A1 (en) * 2000-03-14 2001-09-24 Brown University Research Foundation Methods and compositions for regulating memory consolidation
AU2001257363A1 (en) 2000-04-28 2001-11-12 Georgetown University Rigid pyrrolidone modulators of pkc
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
US20030050302A1 (en) * 2000-08-31 2003-03-13 Neurologic, Inc. Treatment of conditions associated with amyloid processing using PKC activators
DE60028376T2 (de) 2000-10-09 2007-06-06 Rath, Matthias, Dr. Therapeutische Kombination des Ascorbats mit Lysin und Arginin für Verhinderung und Behandlung des Krebses
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
AUPR215700A0 (en) * 2000-12-19 2001-01-25 Fujisawa Pharmaceutical Co., Ltd. Carboxylic acid compound having cyclopropane ring
WO2002069948A1 (en) 2001-03-01 2002-09-12 Pfizer Products Inc. Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders
WO2002083877A1 (en) 2001-04-11 2002-10-24 Stem Cell Therapeutics Inc. Production of tyrosine hydroxylase positive neurons
WO2002086106A1 (en) 2001-04-23 2002-10-31 Nsgene A/S Method and culture medium for producing neural cells expressing tyrosine hydroxylase
ES2314056T3 (es) 2001-05-02 2009-03-16 Blanchette Rockefeller Neurosciences Institute Activadores de la anhidrasa carbonica para mejorar el aprendizaje y la memoria.
CA2401452A1 (en) 2001-09-04 2003-03-04 Uri Saragovi Combination of antioxidant substances for the treatment of alzheimer's disease
JP4568464B2 (ja) 2001-11-07 2010-10-27 雪印乳業株式会社 記憶障害予防治療剤
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6821979B2 (en) 2002-03-07 2004-11-23 Blanchette Rockefeller Neurosciences Institute Synergistic enhancement of cognitive ability
US6825229B2 (en) * 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
AU2003281214A1 (en) * 2002-07-02 2004-01-23 Blanchette Rockefeller Neurosciences Institute PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPAlpha SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
US7803400B2 (en) * 2002-12-03 2010-09-28 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
EA008864B1 (ru) 2003-09-30 2007-08-31 Нью Ривер Фармасьютикалз Инк. Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
EP1761805B1 (en) 2004-06-30 2013-05-01 Shell Internationale Research Maatschappij B.V. Determining in-situ the relation between seismic velocity and state of stress in an underground formation
CA2617003A1 (en) 2005-07-29 2007-02-08 Blanchette Rockefeller Neurosciences Institute Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory
WO2007044094A1 (en) 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
KR20090038478A (ko) * 2006-07-28 2009-04-20 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 세포 성장 자극, 시냅스 리모델링 및 장기간 기억 강화 방법
US9974832B2 (en) 2007-02-09 2018-05-22 Cognitive Research Enterprises, Inc. Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
JP5987867B2 (ja) 2014-07-10 2016-09-07 コニカミノルタ株式会社 シート搬送装置および画像形成システム

Also Published As

Publication number Publication date
EP2121000A2 (en) 2009-11-25
JP5518489B2 (ja) 2014-06-11
JP2014088406A (ja) 2014-05-15
KR20090119894A (ko) 2009-11-20
EP2959914A1 (en) 2015-12-30
EP2121000B1 (en) 2015-09-23
CA2873179A1 (en) 2008-08-21
EP2754448A2 (en) 2014-07-16
WO2008100449A4 (en) 2009-07-30
KR20140049054A (ko) 2014-04-24
EP2754448A3 (en) 2014-12-24
WO2008100449A3 (en) 2009-05-22
US20080207742A1 (en) 2008-08-28
JP2016128486A (ja) 2016-07-14
US20190083575A1 (en) 2019-03-21
CN101848726A (zh) 2010-09-29
US9974832B2 (en) 2018-05-22
JP6199176B2 (ja) 2017-09-20
CA2674773A1 (en) 2008-08-21
JP2010518091A (ja) 2010-05-27
EP3332797A2 (en) 2018-06-13
WO2008100449A2 (en) 2008-08-21
EP3332797A3 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
ES2548766T3 (es) Efectos terapéuticos de las briostatinas, briólogos y otras sustancias relacionadas en alteraciones de la memoria inducidas por trauma craneal y por lesiones cerebrales
ES2272827T3 (es) Parche terapeutico transdermico con capsaicina y analogos de capsaicina.
ES2251939T3 (es) Usos y composiciones para tratar tumores primarios y secundarios del sistema nervioso central (cns).
ES2237461T3 (es) Uso de retigabina para el tratamiento de dolores neuropaticos.
ES2773466T3 (es) Dispositivo guía para intervención
ES2691319T3 (es) Composiciones y métodos para aliviar el dolor sin adormecimiento
ES2381968T3 (es) 2,2'-ditio-bis(etanosulfonato) para su uso en la inhibición de la termoestesia anómala inducida por paclitaxel
KR101244199B1 (ko) 우울증 장애 치료법
ES2220542T3 (es) Combinaciones sinergicas de un antagonista del receptor nk1 y un analogo estructural del gaba.
ES2374503T3 (es) Acetil l-carnitina para la prevención y/o el tratamiento de las neuropatías periféricas inducidas por talidomida.
ES2528033T3 (es) Efectos terapéuticos de las briostatinas sobre la alteración de la memoria inducida por isquemia/accidente vascular cerebral y lesiones cerebrales
Chauhan et al. A comprehensive review on drug therapies and nanomaterials used in orthodontic treatment
WO2008143880A2 (en) Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and traumatic brain injury
ES2268393T3 (es) Terapia con estatina para favorecer el mantenimiento de la funcion cognitiva.
CN101554475B (zh) 次血红素短肽化合物在抗脑缺血药物制备中的用途
RU2296567C1 (ru) Способ химиолучевой терапии злокачественных глиальных опухолей головного мозга
RU2232020C1 (ru) Способ профилактики возникновения пневмоний в раннем послеоперационном периоде
Wiedemann Drug treatment of ocular neovascularization and proliferation
ElAttrache Comparison of the effectiveness of 2% lidocaine with 1: 100,000 epi vs 4% articaine with 1: 100,000 epi on teeth with irreversible pulpitis
Billington Inhibition of angiogenesis as a potential therapeutic strategy
UA22811U (en) Method for treating critical ischemia of lower limbs
UA61371A (en) Method for preventing acute postoperative pancreatitis
UA58568C2 (uk) Спосіб лікування епілепсії
UA71425A (uk) Спосіб лікування хворих на гострий деструктивний панкреатит